Literature DB >> 30770326

Screening for substance use in pregnancy and the newborn.

Kathryn Polak1, Sydney Kelpin2, Mishka Terplan3.   

Abstract

Substance use during pregnancy is common, costly and associated with maternal and newborn health consequences. Assessment of substance use should be integrated into prenatal care. Substance use identification methods include patient interview, screening instruments, and biological testing. In this review, we critically evaluate screening and testing for substance use during pregnancy, highlighting the benefits and barriers of integrated assessment into prenatal care. We also discuss the limitations and negative consequences that should be considered when implementing screening and/or testing procedures. Lastly, we provide recommendations for the ethical implementation of screening and testing for substance use in the context of prenatal care.
© 2019 Published by Elsevier Ltd.

Entities:  

Keywords:  Pregnancy; Screening; Substance use disorder; Testing

Mesh:

Year:  2019        PMID: 30770326     DOI: 10.1016/j.siny.2019.01.007

Source DB:  PubMed          Journal:  Semin Fetal Neonatal Med        ISSN: 1744-165X            Impact factor:   3.926


  1 in total

1.  Early lessons from maternal mortality review committees on drug-related deaths-time for obstetrical providers to take the lead in addressing addiction.

Authors:  Marcela C Smid; Charles W Schauberger; Mishka Terplan; Tricia E Wright
Journal:  Am J Obstet Gynecol MFM       Date:  2020-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.